FAIR PARK II Clinical Trial - Newsletter n°35
Published on 14/06/2019
FAIR PARK II (Conservative Iron Chelation as a Disease-Modifying Strategy in Parkinson's Disease), an ECRIN-supported clinical trial, has released its June 2019 newsletter.
FairPark II is a major EU-funded research project that will primarily investigate the effects of an iron chelation therapy on the progression of handicap in Parkinson's disease.
The project will run for five years (2015 - 2020) and will see 15 partners collaborate on a range of investigations including a multicentre clinical trial of the therapy in Parkinson's disease patients.
